Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
SOLO DMPK & Bioanalysis: from metabolism to regulated bioanalysis for your products
A complete offering to asses and characterize ADME-T (Absorption, Distribution, Metabolism, Excretion, Toxicity properties), pharmacokinetics and regulatory bioanalytical support for chemical or biological entities.
From target to preclinical candidate selection …
Benefit from our experience in numerous preclinical candidate discovery projects in various therapeutic indications
Expert advice to guide the developability of new therapeutic molecule
Smart solutions designed for you:
Execution of ad-hoc in vitro ADME-T predictive studies and/or assessment of pharmacokinetics profiles, PK/PD interactions by different routes of administration
Integrated and optimized design of in vitro and in vivo assays with adapted decision trees from hit discovery to preclinical candidate selection and human dose prediction
… to regulated bioanalysis
Specialized support in regulatory bioanalysis from preclinical to clinical development of new chemical and biological entities
Recognized expertise and know-how in GLP analysis by tandem mass spectrometry, quantitative PCR, flow cytometry and immunoassays (Ligand binding assays & Immunogenicity).